Global Leadership

Stephen P. MacMillan
Chairman, President and Chief Executive Officer

Stephen P. MacMillan
Chairman, President and Chief Executive Officer
Mr. MacMillan joined Hologic in December 2013 as President and CEO, and has led a dramatic turnaround at the Company.
He was elected Chairman of our Board of Directors in June 2015. From 2005 to 2012, Mr. MacMillan served as President and Chief Executive Officer of Stryker Corporation, where he had been President since 2003. During his tenure at Stryker, Mr. MacMillan successfully led the company through a series of key strategic acquisitions, the launch of a number of products within the orthopedic implants and medical instrumentation businesses, and delivered strong operating performance, with revenue tripling from $2.8 billion to $8.3 billion, between 2003 and 2011. Prior to 2003, Mr. MacMillan was a senior executive with Pharmacia Corporation, where he oversaw five global businesses with revenues exceeding $2 billion, including one in diagnostics.
Prior to joining Pharmacia, Mr. MacMillan spent 11 years with Johnson & Johnson in a variety of senior roles both in the U.S. and Europe, including President of the joint venture between Johnson & Johnson and Merck. Mr. MacMillan began his career with Procter and Gamble in 1985. He received a Bachelor of Arts degree in Economics from Davidson College and is a graduate of Harvard Business School’s Advanced Management Program. Mr. MacMillan currently serves as independent director and non-executive chair of Illumina, Inc. and on the board of directors of AdvaMed. Mr. MacMillan previously served on the Boards of Directors of Alere, Inc., Boston Scientific Corporation and Texas Instruments.
He was elected Chairman of our Board of Directors in June 2015. From 2005 to 2012, Mr. MacMillan served as President and Chief Executive Officer of Stryker Corporation, where he had been President since 2003. During his tenure at Stryker, Mr. MacMillan successfully led the company through a series of key strategic acquisitions, the launch of a number of products within the orthopedic implants and medical instrumentation businesses, and delivered strong operating performance, with revenue tripling from $2.8 billion to $8.3 billion, between 2003 and 2011. Prior to 2003, Mr. MacMillan was a senior executive with Pharmacia Corporation, where he oversaw five global businesses with revenues exceeding $2 billion, including one in diagnostics.
Prior to joining Pharmacia, Mr. MacMillan spent 11 years with Johnson & Johnson in a variety of senior roles both in the U.S. and Europe, including President of the joint venture between Johnson & Johnson and Merck. Mr. MacMillan began his career with Procter and Gamble in 1985. He received a Bachelor of Arts degree in Economics from Davidson College and is a graduate of Harvard Business School’s Advanced Management Program. Mr. MacMillan currently serves as independent director and non-executive chair of Illumina, Inc. and on the board of directors of AdvaMed. Mr. MacMillan previously served on the Boards of Directors of Alere, Inc., Boston Scientific Corporation and Texas Instruments.

Amy M. Wendell
Lead Independent Director, Former Senior Vice President, Strategy and Business Development, Covidien plc

Amy M. Wendell
Lead Independent Director, Former Senior Vice President, Strategy and Business Development, Covidien plc
Ms. Wendell was appointed to our Board in December 2016.
From January 2016 to May 2019, Ms. Wendell was a Senior Advisor for Perella Weinberg Partner's Healthcare Investment Banking Practice, providing guidance and advice with respect to mergers and acquisitions and divestitures for clients and assisting the firm in connection with firm-level transactions. From 2015 to September 2018, Ms. Wendell served as a Senior Advisor for McKinsey's Strategy and Corporate Finance Practice and also served as a member of McKinsey's Transactions Advisory Board to help define trends in mergers and acquisitions, as well as help shape McKinsey's knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including engineering, product management and business development. Most recently, from December 2006 until Covidien's acquisition by Medtronic plc in January 2015, she served as Senior Vice President of Strategy and Business Development, where she led the company's strategy and portfolio management initiatives and managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution. Ms. Wendell also serves on the boards of AxoGen, Inc., where she is a member of the Audit Committee and the Compensation Committee; Solventum Corp., where she is a member of the Governance Committee and the Science, Technology and Quality Committee; and at Baxter International, Inc., where she is a member of the Quality, Compliance and Technology Committee. She is Chairman of the Board of Por Cristo, a non-profit charitable medical service organization involved in healthcare work for at-risk women and children in Latin America. Ms. Wendell holds a Bachelor of Science in mechanical engineering from Lawrence Technological University and a Master of Science degree in biomedical engineering from the University of Illinois.
Member of the Compensation Committee
Chair of the Nominating and Corporate Governance Committee
Member of the Compensation Committee
Chair of the Nominating and Corporate Governance Committee

Charles J. Dockendorff
Former CFO and Executive Vice President, Covidien plc

Charles J. Dockendorff
Former CFO and Executive Vice President, Covidien plc
Mr. Dockendorff has been a member of our board since May 2017.
Mr. Dockendorff was formerly Executive Vice President and Chief Financial Officer of Covidien plc, a global medical device and supplies company. He was CFO at Covidien and its predecessor, Tyco Healthcare, from 1995 to 2015. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as Controller and was named Vice President and Controller in 1994. He was appointed Chief Financial Officer of Tyco Healthcare in 1995. Prior to joining Kendall/Tyco Healthcare, Mr. Dockendorff was the Chief Financial Officer, Vice President of Finance and Treasurer of Epsco Inc. and Infrared Industries, Inc. In addition, Mr. Dockendorff worked as an accountant for Arthur Young & Company (now Ernst & Young) and the General Motors Corporation. Mr. Dockendorff is a director of Boston Scientific Corporation, Haemonetics Corporation and Keysight Technologies, Inc. Mr. Dockendorff holds a bachelor’s degree in accounting from the University of Massachusetts at Amherst and a M.S. in finance from Bentley College.
Chair of the Audit and Finance Committee

Ludwig N. Hantson
Former Chief Executive Officer, Alexion Pharmaceuticals, Inc.

Ludwig N. Hantson
Former Chief Executive Officer, Alexion Pharmaceuticals, Inc.
Dr. Hantson was appointed to our Board in November 2018.
Dr. Hantson was formerly Chief Executive Officer of Alexion Pharmaceuticals, Inc. from March 2017 to July 2021, when Alexion was acquired by AstraZeneca PLC. Prior to joining Alexion, he was President and Chief Executive Officer of Baxalta Incorporated. In July 2015, Dr. Hantson led Baxalta’s successful spin-off as a public company from Baxter International Inc., where he was President of Baxter BioScience. He joined Baxter in May 2010 and established the BioScience division as an innovative specialty and rare disease company. Prior to Baxter, from 2001 - 2010, Dr. Hantson held several leadership roles at Novartis AG, including CEO of Pharma North America, CEO of Europe, and President of Pharma Canada. Prior to Novartis, he spent 13 years with Johnson & Johnson in roles of increasing responsibility in marketing and R&D. Dr. Hantson previously served on the board of Baxalta. He received his Ph.D. in motor rehabilitation and physical therapy, master’s degree in physical education, and a certification in high secondary education, all from the University of Louvain in Belgium.
- Phone:+1 (859) 254-6589
- Email:info@example.com

Stacey D. Stewart
CEO of Mothers Against Drunk Driving (MADD)

Stacey D. Stewart
CEO of Mothers Against Drunk Driving (MADD)
Ms. Stewart has been a member of our board since January 2023.
Ms. Stewart was named Chief Executive Officer of Mothers Against Drunk Driving in January 2023. She previously served as President & CEO of March of Dimes Inc., a leading nonprofit organization, from November 2016 to December 2022. From June 2009 to November 2016, Ms. Stewart served in various executive positions, including U.S. President of operations and executive vice president for Community Impact Leadership and Learning at United Way Worldwide, the world's largest charitable organization. From February 2007 to April 2009, Ms. Stewart was a senior vice president of Fannie Mae, a government-sponsored enterprise that supports liquidity and stability in the secondary mortgage market. Ms. Stewart is a director of PennyMac Mortgage Investment Trust. Ms. Stewart holds a Bachelor of Arts from Georgetown University and a Master of Business Administration from the University of Michigan.
- Phone:+1 (859) 254-6589
- Email:info@example.com